Skip to main content

Table 1 Composition of rosuvastatin chitosomes nanoparticles formulations and the obtained values for the studied responses

From: Development of rosuvastatin flexible lipid-based nanoparticles: promising nanocarriers for improving intestinal cells cytotoxicity

Run

X1

(MR)

X2

(%)

X3

(%)

Y1

Y2

(%)

Y3

(mV)

Size (nm)

PDI

1

1.0

0.01

0.4

239.48 ± 5.33

0.344 ± 0.065

90.88 ± 1.65

12.66 ± 1.58

2

4.0

0.04

0.4

225.27 ± 6.59

0.425 ± 0.095

86.94 ± 4.94

18.10 ± 3.38

3

2.5

0.04

0.2

112.19 ± 2.90

0.288 ± 0.009

85.14 ± 5.04

− 1.83 ± 0.55

4

2.5

0.01

0.6

554.33 ± 11.06

0.573 ± 0.045

94.59 ± 1.62

26.74 ± 0.26

5

2.5

0.04

0.6

507.40 ± 18.14

0.581 ± 0.051

91.97 ± 4.89

26.07 ± 1.90

6

4.0

0.01

0.4

295.40 ± 5.11

0.258 ± 0.023

88.75 ± 3.99

10.70 ± 0.16

7

4.0

0.025

0.6

547.33 ± 20.09

0.511 ± 0.024

92.79 ± 1.76

28.87 ± 1.39

8

2.5

0.01

0.2

163.13 ± 3.29

0.391 ± 0.053

87.94 ± 2.04

− 8.14 ± 0.51

9

1.0

0.025

0.6

535.33 ± 43.12

0.543 ± 0.053

93.22 ± 1.24

27.23 ± 0.31

10

1.0

0.025

0.2

132.77 ± 4.46

0.439 ± 0.061

87.61 ± 2.07

−10.07 ± 1.26

11

1.0

0.04

0.4

219.53 ± 6.36

0.354 ± 0.071

90.63 ± 2.15

13.15 ± 0.75

12

4.0

0.025

0.2

132.97 ± 2.11

0.318 ± 0.022

84.78 ± 3.09

−6.92 ± 0.16

13

2.5

0.025

0.4

255.83 ± 8.37

0.394 ± 0.128

85.44 ± 2.21

11.26 ± 2.04

14

2.5

0.025

0.4

252.30 ± 3.84

0.318 ± 0.088

86.38 ± 3.03

11.83 ± 2.67

15

2.5

0.025

0.4

259.77 ± 3.69

0.382 ± 0.043

85.15 ± 4.07

14.87 ± 1.89

  1. Abbreviations: X1 Drug to phospholipid, X2 Surfactant concentration, X3 Coating solution concentration, Y1 Particle size (nm,Y2 Entrapment efficiency (%), Y3 Zeta potential (mV), MR Molar ratio, PDI Poly dispersity index